Literature DB >> 20019322

Estimating the risks and benefits of nicotine replacement therapy for smoking cessation in the United States.

Benjamin J Apelberg1, Georgiana Onicescu, Erika Avila-Tang, Jonathan M Samet.   

Abstract

OBJECTIVES: To compare potential population-wide benefits and risks, we examined the potential impact of increased nicotine replacement therapy (NRT) use for smoking cessation on future US mortality.
METHODS: We developed a simulation model incorporating a Monte Carlo uncertainty analysis, with data from the 2005 National Health Interview Survey and Cancer Prevention Study II. We estimated the number of avoided premature deaths from smoking attributable to increased NRT use, before and after incorporating assumptions about NRT harm.
RESULTS: We estimate that a gradual increase in the proportion of NRT-aided quit attempts to 100% by 2025 would lead to 40,000 (95% credible interval=31,000, 50,000) premature deaths avoided over a 20-year period. Most avoided deaths would be attributable to lung cancer and cardiovascular disease. After we incorporated assumptions about potential risk from long-term NRT, the estimate of avoided premature deaths from all causes declined to 32 000.
CONCLUSIONS: Even after we assumed some harm from long-term NRT use, the benefits from increased cessation success far outweigh the risks. However, the projected reduction in premature mortality still reflects a small portion of the tobacco-related deaths expected over a 20-year period.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20019322      PMCID: PMC2804631          DOI: 10.2105/AJPH.2008.147223

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  40 in total

1.  Cigarette smoking among adults--United States, 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-26       Impact factor: 17.586

Review 2.  Shape of the relapse curve and long-term abstinence among untreated smokers.

Authors:  John R Hughes; Josue Keely; Shelly Naud
Journal:  Addiction       Date:  2004-01       Impact factor: 6.526

Review 3.  Actual causes of death in the United States, 2000.

Authors:  Ali H Mokdad; James S Marks; Donna F Stroup; Julie L Gerberding
Journal:  JAMA       Date:  2004-03-10       Impact factor: 56.272

Review 4.  Smokeless tobacco and cardiovascular risk.

Authors:  Ritesh Gupta; Hitinder Gurm; John R Bartholomew
Journal:  Arch Intern Med       Date:  2004-09-27

Review 5.  Smokeless tobacco and cardiovascular disease.

Authors:  Kjell Asplund
Journal:  Prog Cardiovasc Dis       Date:  2003 Mar-Apr       Impact factor: 8.194

Review 6.  Screening for lung cancer.

Authors:  R L Manser; L B Irving; C Stone; G Byrnes; M Abramson; D Campbell
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 7.  Nicotine and angiogenesis: a new paradigm for tobacco-related diseases.

Authors:  John P Cooke; Haim Bitterman
Journal:  Ann Med       Date:  2004       Impact factor: 4.709

Review 8.  Nicotine replacement therapy for smoking cessation.

Authors:  C Silagy; T Lancaster; L Stead; D Mant; G Fowler
Journal:  Cochrane Database Syst Rev       Date:  2004

9.  Smoking habits and tar levels in a new American Cancer Society prospective study of 1.2 million men and women.

Authors:  S D Stellman; L Garfinkel
Journal:  J Natl Cancer Inst       Date:  1986-06       Impact factor: 13.506

10.  Mortality in relation to smoking: 50 years' observations on male British doctors.

Authors:  Richard Doll; Richard Peto; Jillian Boreham; Isabelle Sutherland
Journal:  BMJ       Date:  2004-06-22
View more
  12 in total

1.  Nicotine aggravates the brain postischemic inflammatory response.

Authors:  Shayna T Bradford; Svetlana M Stamatovic; Raj S Dondeti; Richard F Keep; Anuska V Andjelkovic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-14       Impact factor: 4.733

Review 2.  Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers.

Authors:  Courtney Schaal; Srikumar P Chellappan
Journal:  Mol Cancer Res       Date:  2014-01-07       Impact factor: 5.852

3.  Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis.

Authors:  Sharon E Murphy; Linda B von Weymarn; Melissa M Schutten; Fekadu Kassie; Jaime F Modiano
Journal:  Cancer Prev Res (Phila)       Date:  2011-10-25

4.  Smoking cessation: benefits versus risks of using pharmacotherapy to quit.

Authors:  Jonathan M Samet
Journal:  Circulation       Date:  2013-12-09       Impact factor: 29.690

5.  Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study.

Authors:  Riccardo Polosa; Jaymin B Morjaria; Pasquale Caponnetto; Davide Campagna; Cristina Russo; Angela Alamo; MariaDomenica Amaradio; Alfredo Fisichella
Journal:  Intern Emerg Med       Date:  2013-07-20       Impact factor: 3.397

6.  Nicotine replacement therapy for the palliation of nicotine abstinence syndrome: boon more than bane.

Authors:  Roshan Bhad; Nandita Hazari
Journal:  Indian J Palliat Care       Date:  2015 May-Aug

7.  Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit.

Authors:  Riccardo Polosa; Pasquale Caponnetto; Marilena Maglia; Jaymin B Morjaria; Cristina Russo
Journal:  BMC Public Health       Date:  2014-11-08       Impact factor: 3.295

Review 8.  E-cigarettes and smoking cessation: evidence from a systematic review and meta-analysis.

Authors:  Muhammad Aziz Rahman; Nicholas Hann; Andrew Wilson; George Mnatzaganian; Linda Worrall-Carter
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

9.  Population-based survey of cessation aids used by Swedish smokers.

Authors:  Lars E Rutqvist
Journal:  Harm Reduct J       Date:  2012-12-04

10.  Stillbirth Among Women Prescribed Nicotine Replacement Therapy in Pregnancy: Analysis of a Large UK Pregnancy Cohort.

Authors:  Nafeesa N Dhalwani; Lisa Szatkowski; Tim Coleman; Linda Fiaschi; Laila J Tata
Journal:  Nicotine Tob Res       Date:  2019-03-30       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.